Alzheimer's Disease Neuroimaging Initiative View Homepage


Ontology type: schema:MonetaryGrant     


Grant Info

YEARS

2004-2016

FUNDING AMOUNT

121015368 USD

ABSTRACT

DESCRIPTION (provided by applicant): The goal of this project is to determine relationships among the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD), as pathology evolves from normal aging to very mild symptoms, to mild cognitive impairment (MCI), to dementia. ADNl will inform the neuroscience of AD, identify diagnostic and prognostic markers, identify outcome measures that can be used in clinical trials, and help develop the most effective clinical trial scenarios. ADNI2 continues the currently funded AD Neuroimaging Initiative (ADNI1), a public/private collaboration between academia and industry to study biomarkers of AD as well as a recently funded Grand Opportunities grant that supplements ADNl goals and activities (GO). New aspects of ADNl include enrolling subjects with early MCI (EMCI), F18 amyloid imaging, and obtaining all clinical/cognitive, lumbar puncture CSF and plasma biomarker, and MRI/PET data on all subjects. The goals of this ADNl renewal will be accomplished by: 1) continuing annual clinical/cognitive/MRI follow up of the 476 normal controls and late MCI (LMCI) subjects previously enrolled in ADNI1; 2) following the 200 EMCI subjects enrolled in the GO ADNl grant; 3) additional enrollment of new healthy controls (n=150), EMCI (n=100 which adds to the 200 subjects enrolled in GO), LMCI (n=150), and AD (n=150) subjects; 4) performance of F18 amyloid PET (using F18 AV-45 from AVID, Inc.) on all new subjects enrolled in ADNI2, together with FDG PET, and to obtain a 2nd F18 amyloid PET on all remaining ADNI1, GO, and ADNI2 subjects 2 years after the baseline scan; 5) continue to obtain annual clinical/cognitive/blood draw/lumbar puncture for CSF, and MRI on all subjects. All collected data will be processed and analyzed by ADNl investigators including the Biostatistical Core, and made available to all qualified scientists in the world who request a password, without embargo. Hypotheses developed from current ADNl data will be replicated and new hypotheses tested, especially concerning EMCI and F18 amyloid imaging. ADNl spawned large multisite projects in other countries. No other large multisite study in the world addresses these complex issues with the sample size and statistical power of this application. More... »

URL

http://projectreporter.nih.gov/project_info_description.cfm?aid=9145042

Related SciGraph Publications

  • 2019-12. A blood-based signature of cerebrospinal fluid Aβ1–42 status in SCIENTIFIC REPORTS
  • 2019-12. Covariance statistics and network analysis of brain PET imaging studies in SCIENTIFIC REPORTS
  • 2019-12. Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers in ALZHEIMER'S RESEARCH & THERAPY
  • 2019-12. Predicting Alzheimer’s disease progression using multi-modal deep learning approach in SCIENTIFIC REPORTS
  • 2019-12. Inferior and medial temporal tau and cortical amyloid are associated with daily functional impairment in Alzheimer’s disease in ALZHEIMER'S RESEARCH & THERAPY
  • 2019-12. Predicting Short-term MCI-to-AD Progression Using Imaging, CSF, Genetic Factors, Cognitive Resilience, and Demographics in SCIENTIFIC REPORTS
  • 2019-12. MultiLink Analysis: Brain Network Comparison via Sparse Connectivity Analysis in SCIENTIFIC REPORTS
  • 2019-12. Lifespan Changes of the Human Brain In Alzheimer’s Disease in SCIENTIFIC REPORTS
  • 2019-03-27. Sign-Consistency Based Variable Importance for Machine Learning in Brain Imaging in NEUROINFORMATICS
  • 2019-03-01. Network Analysis of Depression-Related Transcriptomic Profiles in NEUROMOLECULAR MEDICINE
  • 2019-02. Association of cerebrospinal fluid Neurogranin with Alzheimer’s disease in AGING CLINICAL AND EXPERIMENTAL RESEARCH
  • 2019-02. Robust multi-label transfer feature learning for early diagnosis of Alzheimer’s disease in BRAIN IMAGING AND BEHAVIOR
  • 2019-02. Altered effective connectivity anchored in the posterior cingulate cortex and the medial prefrontal cortex in cognitively intact elderly APOE ε4 carriers: a preliminary study in BRAIN IMAGING AND BEHAVIOR
  • 2019-02. Accuracy and generalization capability of an automatic method for the detection of typical brain hypometabolism in prodromal Alzheimer disease in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2019-02. Identify a shared neural circuit linking multiple neuropsychiatric symptoms with Alzheimer’s pathology in BRAIN IMAGING AND BEHAVIOR
  • 2019-02. A methodological approach to studying resilience mechanisms: demonstration of utility in age and Alzheimer’s disease-related brain pathology in BRAIN IMAGING AND BEHAVIOR
  • 2019-02. Diagnostic and prognostic value of amyloid PET textural and shape features: comparison with classical semi-quantitative rating in 760 patients from the ADNI-2 database in BRAIN IMAGING AND BEHAVIOR
  • 2019-01-28. Estimation of the volume under the ROC surface in presence of nonignorable verification bias in STATISTICAL METHODS & APPLICATIONS
  • 2019-01. Identification of exon skipping events associated with Alzheimer’s disease in the human hippocampus in BMC MEDICAL GENOMICS
  • 2019. Prediction of Alzheimer’s Disease in Mild Cognitive Impairment Using Sulcal Morphology and Cortical Thickness in WORLD CONGRESS ON MEDICAL PHYSICS AND BIOMEDICAL ENGINEERING 2018
  • 2018-12-04. Genetic data and cognitively defined late-onset Alzheimer’s disease subgroups in MOLECULAR PSYCHIATRY
  • 2018-12. Inter-network connectivity and amyloid-beta linked to cognitive decline in preclinical Alzheimer’s disease: a longitudinal cohort study in ALZHEIMER'S RESEARCH & THERAPY
  • 2018-12. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer’s disease in ALZHEIMER'S RESEARCH & THERAPY
  • 2018-12. Uncovering the heterogeneity and temporal complexity of neurodegenerative diseases with Subtype and Stage Inference in NATURE COMMUNICATIONS
  • 2018-12. Multimodal and Multiscale Deep Neural Networks for the Early Diagnosis of Alzheimer’s Disease using structural MR and FDG-PET images in SCIENTIFIC REPORTS
  • 2018-12. Characteristic patterns of inter- and intra-hemispheric metabolic connectivity in patients with stable and progressive mild cognitive impairment and Alzheimer’s disease in SCIENTIFIC REPORTS
  • 2018-12. Genome-wide association study identified ATP6V1H locus influencing cerebrospinal fluid BACE activity in BMC MEDICAL GENETICS
  • 2018-12. Brain multiplexes reveal morphological connectional biomarkers fingerprinting late brain dementia states in SCIENTIFIC REPORTS
  • 2018-12. Volumetric comparison of hippocampal subfields extracted from 4-minute accelerated vs. 8-minute high-resolution T2-weighted 3T MRI scans in BRAIN IMAGING AND BEHAVIOR
  • 2018-12. Blind blur assessment of MRI images using parallel multiscale difference of Gaussian filters in BIOMEDICAL ENGINEERING ONLINE
  • 2018-12. Genome-wide association study identifies two loci influencing plasma neurofilament light levels in BMC MEDICAL GENOMICS
  • 2018-12. Neuropsychological predictors of conversion from mild cognitive impairment to Alzheimer’s disease: a feature selection ensemble combining stability and predictability in BMC MEDICAL INFORMATICS AND DECISION MAKING
  • 2018-12. Sex Differences in Cognitive Decline in Subjects with High Likelihood of Mild Cognitive Impairment due to Alzheimer’s disease in SCIENTIFIC REPORTS
  • 2018-12. Stability of graph theoretical measures in structural brain networks in Alzheimer’s disease in SCIENTIFIC REPORTS
  • 2018-12. The utility of a network–based clustering method for dimension reduction of imaging and non-imaging biomarkers predictive of Alzheimer’s disease in SCIENTIFIC REPORTS
  • 2018-12. Cerebrospinal fluid phosphorylated tau, visinin-like protein-1, and chitinase-3-like protein 1 in mild cognitive impairment and Alzheimer’s disease in TRANSLATIONAL NEURODEGENERATION
  • 2018-12. The A/T/N biomarker scheme and patterns of brain atrophy assessed in mild cognitive impairment in SCIENTIFIC REPORTS
  • 2018-12. Structural brain imaging in Alzheimer’s disease and mild cognitive impairment: biomarker analysis and shared morphometry database in SCIENTIFIC REPORTS
  • 2018-12. Aberrant functional connectivity network in subjective memory complaint individuals relates to pathological biomarkers in TRANSLATIONAL NEURODEGENERATION
  • 2018-12. Alzheimer’s disease diagnosis based on the Hippocampal Unified Multi-Atlas Network (HUMAN) algorithm in BIOMEDICAL ENGINEERING ONLINE
  • 2018-12. Machine learning identified an Alzheimer’s disease-related FDG-PET pattern which is also expressed in Lewy body dementia and Parkinson’s disease dementia in SCIENTIFIC REPORTS
  • 2018-12. Systematic Analysis and Biomarker Study for Alzheimer’s Disease in SCIENTIFIC REPORTS
  • 2018-12. Disease-related patterns of in vivo pathology in Corticobasal syndrome in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
  • 2018-12. Unfavourable gender effect of high body mass index on brain metabolism and connectivity in SCIENTIFIC REPORTS
  • 2018-12. Standardized quality metric system for structural brain magnetic resonance images in multi-center neuroimaging study in BMC MEDICAL IMAGING
  • 2018-12. Sex-specific genetic predictors of Alzheimer’s disease biomarkers in ACTA NEUROPATHOLOGICA
  • 2018-11-20. Generation and quality control of lipidomics data for the alzheimer’s disease neuroimaging initiative cohort in SCIENTIFIC DATA
  • 2018-11-09. Early Diagnosis of Alzheimer’s Disease by Ensemble Deep Learning Using FDG-PET in INTELLIGENCE SCIENCE AND BIG DATA ENGINEERING
  • 2018-11. Salient networks: a novel application to study Alzheimer disease in BIOMEDICAL ENGINEERING ONLINE
  • 2018-10-25. Genome-wide association study of brain amyloid deposition as measured by Pittsburgh Compound-B (PiB)-PET imaging in MOLECULAR PSYCHIATRY
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2211", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/2211", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }
        ], 
        "amount": {
          "currency": "USD", 
          "type": "MonetaryAmount", 
          "value": "121015368"
        }, 
        "description": "DESCRIPTION (provided by applicant): The goal of this project is to determine relationships among the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD), as pathology evolves from normal aging to very mild symptoms, to mild cognitive impairment (MCI), to dementia. ADNl will inform the neuroscience of AD, identify diagnostic and prognostic markers, identify outcome measures that can be used in clinical trials, and help develop the most effective clinical trial scenarios. ADNI2 continues the currently funded AD Neuroimaging Initiative (ADNI1), a public/private collaboration between academia and industry to study biomarkers of AD as well as a recently funded Grand Opportunities grant that supplements ADNl goals and activities (GO). New aspects of ADNl include enrolling subjects with early MCI (EMCI), F18 amyloid imaging, and obtaining all clinical/cognitive, lumbar puncture CSF and plasma biomarker, and MRI/PET data on all subjects. The goals of this ADNl renewal will be accomplished by: 1) continuing annual clinical/cognitive/MRI follow up of the 476 normal controls and late MCI (LMCI) subjects previously enrolled in ADNI1; 2) following the 200 EMCI subjects enrolled in the GO ADNl grant; 3) additional enrollment of new healthy controls (n=150), EMCI (n=100 which adds to the 200 subjects enrolled in GO), LMCI (n=150), and AD (n=150) subjects; 4) performance of F18 amyloid PET (using F18 AV-45 from AVID, Inc.) on all new subjects enrolled in ADNI2, together with FDG PET, and to obtain a 2nd F18 amyloid PET on all remaining ADNI1, GO, and ADNI2 subjects 2 years after the baseline scan; 5) continue to obtain annual clinical/cognitive/blood draw/lumbar puncture for CSF, and MRI on all subjects. All collected data will be processed and analyzed by ADNl investigators including the Biostatistical Core, and made available to all qualified scientists in the world who request a password, without embargo. Hypotheses developed from current ADNl data will be replicated and new hypotheses tested, especially concerning EMCI and F18 amyloid imaging. ADNl spawned large multisite projects in other countries. No other large multisite study in the world addresses these complex issues with the sample size and statistical power of this application.", 
        "endDate": "2016-07-31T00:00:00Z", 
        "funder": {
          "id": "https://www.grid.ac/institutes/grid.419475.a", 
          "type": "Organization"
        }, 
        "id": "sg:grant.2687006", 
        "identifier": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "2687006"
            ]
          }, 
          {
            "name": "nih_id", 
            "type": "PropertyValue", 
            "value": [
              "U01AG024904"
            ]
          }
        ], 
        "inLanguage": [
          "en"
        ], 
        "keywords": [
          "normal controls", 
          "GO", 
          "password", 
          "late MCI", 
          "Alzheimer's Disease Neuroimaging Initiative", 
          "imaging", 
          "relationship", 
          "avid", 
          "new hypothesis", 
          "data", 
          "entire spectrum", 
          "ADNl investigators", 
          "blood", 
          "academia", 
          "early MCI", 
          "hypothesis", 
          "additional enrollment", 
          "normal aging", 
          "pathology", 
          "baseline scan", 
          "new healthy controls", 
          "new subject", 
          "CSF", 
          "description", 
          "applicants", 
          "MRI", 
          "complex issues", 
          "mild symptoms", 
          "neuroscience", 
          "ADNI2", 
          "ADNl", 
          "statistical power", 
          "F18 AV-45", 
          "Alzheimer's disease", 
          "other large multisite study", 
          "biomarkers", 
          "Supplement", 
          "F18 amyloid imaging", 
          "EMCI subjects", 
          "outcome measures", 
          "plasma biomarkers", 
          "lumbar puncture", 
          "effective clinical trial scenarios", 
          "MRI/PET data", 
          "application", 
          "ADNl renewal", 
          "subjects", 
          "prognostic marker", 
          "world", 
          "Biostatistical Core", 
          "industry", 
          "qualified scientists", 
          "mild cognitive impairment", 
          "private collaboration", 
          "dementia", 
          "ADNI2 subjects 2 years", 
          "biochemical biomarker characteristics", 
          "new aspects", 
          "lumbar puncture CSF", 
          "GO ADNl grant", 
          "activity", 
          "Grand Opportunities", 
          "sample size", 
          "project", 
          "large multisite projects", 
          "performance", 
          "Inc.", 
          "goal", 
          "FDG PET", 
          "clinical trials", 
          "ADNI1", 
          "F18 amyloid PET", 
          "2nd F18 amyloid PET", 
          "AD Neuroimaging Initiative", 
          "embargo", 
          "current ADNl data", 
          "other countries"
        ], 
        "name": "Alzheimer's Disease Neuroimaging Initiative", 
        "recipient": [
          {
            "id": "https://www.grid.ac/institutes/grid.280122.b", 
            "type": "Organization"
          }, 
          {
            "affiliation": {
              "id": "https://www.grid.ac/institutes/grid.280122.b", 
              "name": "NORTHERN CALIFORNIA INSTITUTE/RES/EDU", 
              "type": "Organization"
            }, 
            "familyName": "WEINER", 
            "givenName": "MICHAEL W", 
            "id": "sg:person.016241406277.15", 
            "type": "Person"
          }, 
          {
            "member": "sg:person.016241406277.15", 
            "roleName": "PI", 
            "type": "Role"
          }
        ], 
        "sameAs": [
          "https://app.dimensions.ai/details/grant/grant.2687006"
        ], 
        "sdDataset": "grants", 
        "sdDatePublished": "2019-03-07T12:07", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com.uberresearch.data.processor/core_data/20181219_192338/projects/base/nih_projects_19.xml.gz", 
        "startDate": "2004-09-30T00:00:00Z", 
        "type": "MonetaryGrant", 
        "url": "http://projectreporter.nih.gov/project_info_description.cfm?aid=9145042"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/grant.2687006'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/grant.2687006'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/grant.2687006'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/grant.2687006'


     

    This table displays all metadata directly associated to this object as RDF triples.

    121 TRIPLES      19 PREDICATES      98 URIs      90 LITERALS      5 BLANK NODES

    Subject Predicate Object
    1 sg:grant.2687006 schema:about anzsrc-for:2211
    2 schema:amount N719d094d03f4419bbd99f5ad735629d1
    3 schema:description DESCRIPTION (provided by applicant): The goal of this project is to determine relationships among the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD), as pathology evolves from normal aging to very mild symptoms, to mild cognitive impairment (MCI), to dementia. ADNl will inform the neuroscience of AD, identify diagnostic and prognostic markers, identify outcome measures that can be used in clinical trials, and help develop the most effective clinical trial scenarios. ADNI2 continues the currently funded AD Neuroimaging Initiative (ADNI1), a public/private collaboration between academia and industry to study biomarkers of AD as well as a recently funded Grand Opportunities grant that supplements ADNl goals and activities (GO). New aspects of ADNl include enrolling subjects with early MCI (EMCI), F18 amyloid imaging, and obtaining all clinical/cognitive, lumbar puncture CSF and plasma biomarker, and MRI/PET data on all subjects. The goals of this ADNl renewal will be accomplished by: 1) continuing annual clinical/cognitive/MRI follow up of the 476 normal controls and late MCI (LMCI) subjects previously enrolled in ADNI1; 2) following the 200 EMCI subjects enrolled in the GO ADNl grant; 3) additional enrollment of new healthy controls (n=150), EMCI (n=100 which adds to the 200 subjects enrolled in GO), LMCI (n=150), and AD (n=150) subjects; 4) performance of F18 amyloid PET (using F18 AV-45 from AVID, Inc.) on all new subjects enrolled in ADNI2, together with FDG PET, and to obtain a 2nd F18 amyloid PET on all remaining ADNI1, GO, and ADNI2 subjects 2 years after the baseline scan; 5) continue to obtain annual clinical/cognitive/blood draw/lumbar puncture for CSF, and MRI on all subjects. All collected data will be processed and analyzed by ADNl investigators including the Biostatistical Core, and made available to all qualified scientists in the world who request a password, without embargo. Hypotheses developed from current ADNl data will be replicated and new hypotheses tested, especially concerning EMCI and F18 amyloid imaging. ADNl spawned large multisite projects in other countries. No other large multisite study in the world addresses these complex issues with the sample size and statistical power of this application.
    4 schema:endDate 2016-07-31T00:00:00Z
    5 schema:funder https://www.grid.ac/institutes/grid.419475.a
    6 schema:identifier N7f0fbd3602a44dff85b48a5632d6e203
    7 Ne27d5d555a8a4bcdaf5e4a9ba18bc9ec
    8 schema:inLanguage en
    9 schema:keywords 2nd F18 amyloid PET
    10 AD Neuroimaging Initiative
    11 ADNI1
    12 ADNI2
    13 ADNI2 subjects 2 years
    14 ADNl
    15 ADNl investigators
    16 ADNl renewal
    17 Alzheimer's Disease Neuroimaging Initiative
    18 Alzheimer's disease
    19 Biostatistical Core
    20 CSF
    21 EMCI subjects
    22 F18 AV-45
    23 F18 amyloid PET
    24 F18 amyloid imaging
    25 FDG PET
    26 GO
    27 GO ADNl grant
    28 Grand Opportunities
    29 Inc.
    30 MRI
    31 MRI/PET data
    32 Supplement
    33 academia
    34 activity
    35 additional enrollment
    36 applicants
    37 application
    38 avid
    39 baseline scan
    40 biochemical biomarker characteristics
    41 biomarkers
    42 blood
    43 clinical trials
    44 complex issues
    45 current ADNl data
    46 data
    47 dementia
    48 description
    49 early MCI
    50 effective clinical trial scenarios
    51 embargo
    52 entire spectrum
    53 goal
    54 hypothesis
    55 imaging
    56 industry
    57 large multisite projects
    58 late MCI
    59 lumbar puncture
    60 lumbar puncture CSF
    61 mild cognitive impairment
    62 mild symptoms
    63 neuroscience
    64 new aspects
    65 new healthy controls
    66 new hypothesis
    67 new subject
    68 normal aging
    69 normal controls
    70 other countries
    71 other large multisite study
    72 outcome measures
    73 password
    74 pathology
    75 performance
    76 plasma biomarkers
    77 private collaboration
    78 prognostic marker
    79 project
    80 qualified scientists
    81 relationship
    82 sample size
    83 statistical power
    84 subjects
    85 world
    86 schema:name Alzheimer's Disease Neuroimaging Initiative
    87 schema:recipient Nafe0b781261c431ba67b2494e928c128
    88 sg:person.016241406277.15
    89 https://www.grid.ac/institutes/grid.280122.b
    90 schema:sameAs https://app.dimensions.ai/details/grant/grant.2687006
    91 schema:sdDatePublished 2019-03-07T12:07
    92 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    93 schema:sdPublisher N594681c524ff43248377330d2df48b6d
    94 schema:startDate 2004-09-30T00:00:00Z
    95 schema:url http://projectreporter.nih.gov/project_info_description.cfm?aid=9145042
    96 sgo:license sg:explorer/license/
    97 sgo:sdDataset grants
    98 rdf:type schema:MonetaryGrant
    99 N594681c524ff43248377330d2df48b6d schema:name Springer Nature - SN SciGraph project
    100 rdf:type schema:Organization
    101 N719d094d03f4419bbd99f5ad735629d1 schema:currency USD
    102 schema:value 121015368
    103 rdf:type schema:MonetaryAmount
    104 N7f0fbd3602a44dff85b48a5632d6e203 schema:name nih_id
    105 schema:value U01AG024904
    106 rdf:type schema:PropertyValue
    107 Nafe0b781261c431ba67b2494e928c128 schema:member sg:person.016241406277.15
    108 schema:roleName PI
    109 rdf:type schema:Role
    110 Ne27d5d555a8a4bcdaf5e4a9ba18bc9ec schema:name dimensions_id
    111 schema:value 2687006
    112 rdf:type schema:PropertyValue
    113 anzsrc-for:2211 schema:inDefinedTermSet anzsrc-for:
    114 rdf:type schema:DefinedTerm
    115 sg:person.016241406277.15 schema:affiliation https://www.grid.ac/institutes/grid.280122.b
    116 schema:familyName WEINER
    117 schema:givenName MICHAEL W
    118 rdf:type schema:Person
    119 https://www.grid.ac/institutes/grid.280122.b schema:name NORTHERN CALIFORNIA INSTITUTE/RES/EDU
    120 rdf:type schema:Organization
    121 https://www.grid.ac/institutes/grid.419475.a schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...